Loading
DSB2455 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
The registry describes DSB2455 as a PARP1-selective inhibitor; the sponsor describes CNS activity. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. The sponsor reports FDA Fast Track designation for HRR-altered TNBC brain metastases. Fast Track is a development designation, not marketing approval.
The registry describes DSB2455 as a PARP1-selective inhibitor; the sponsor describes CNS activity. Connects to PARP.
1.DSB2455 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DSB2455" OR ABSTRACT:"DSB2455") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DSB2455, not a curated reading list.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Prostate cancer.
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/